From the Advisory Board

June 2023, Vol 4, No 2 — June 30, 2023
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a unique malignancy comprised of both hepatocellular carcinoma (HCC) from hepatocytes and cholangiocarcinoma (CCA) from bile duct epithelial cells within the same tumor. Initially thought to be a rare entity, the incidence is increasing (up to 14%), yet recognition remains low.
Read More

September 2022, Vol 3, No 3 — September 28, 2022
Surgery remains the only potentially curative modality for cholangiocarcinoma (CCA) in any site of origin.
Read More

June/July 2022, Vol 3, No 2 — August 18, 2022
Recent advances in genomic profiling and critical understanding of pathophysiology have led to the development of multiple targeted therapies in addition to chemotherapeutic agents.
Read More

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: